This Website uses proprietary and third-party cookies to improve services and facilitate browsing. You can obtain further information about the cookies this site uses and how to limit them in the
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Gate2Brain, a cutting-edge technology platform dedicated to overcoming biological barriers—including the blood-brain barrier—has achieved a significant milestone in the fight against brain tumors. The European Medicines Agency (EMA) has recently granted Orphan Drug Designation (ODD) to its innovative product, G2B-002.
Join us in our transformative Series A funding round, currently in design and supported by a 50% co-investment from the European Innovation Council and SMEs Executive Agency (EISMEA) EIC Accelerator.
This is your chance to contribute to scaling a breakthrough technology poised to redefine therapeutic delivery across biological barriers, enabling innovative brain delivery solutions and achieving our shared goal of bringing these groundbreaking products to patients.
Be sure to join us to learn more about Gate2Brain’s novel technology for the delivery of therapeutics across biological barriers. A platform ready for R&D and out-licensing agreements.
Join us for a one-to-one meeting 👇
➡️ https://resiconference.com/partnering/
Or contact us at 📧 carles.taule@gate2brain.com
📅 If your schedule doesn’t allow you to meet us at RESI London, please note that we will also be at JP Morgan Resi San Francisco from January 14th to 16th, 2025, where we will be delivering a 🗣️ pitch. Don’t hesitate to reach out so we can arrange a meeting at one of these events.
We look forward to meeting you there!